gms | German Medical Science

76th Annual Meeting of the German Society of Oto-Rhino-Laryngology, Head and Neck Surgery

German Society of Oto-Rhino-Laryngology, Head and Neck Surgery

04.05. - 08.05.2005, Erfurt

Prestimulation of Head and Neck Cancer Cells with Growth Factors effects enhanced Treatment Efficacy

Meeting Abstract

  • corresponding author Markus Hambek - ENT-Center, University Frankfurt, Frankfurt/Main
  • Christian Werner - ENT-Center, University Frankfurt, Frankfurt/Main
  • Mehran Baghi - ENT-Center, University Frankfurt, Frankfurt/Main
  • Wolfgang Gstöttner - ENT-Center, University Frankfurt, Frankfurt/Main
  • Rainald Knecht - ENT-Center, University Frankfurt, Frankfurt/Main

Deutsche Gesellschaft für Hals-Nasen-Ohren-Heilkunde, Kopf- und Hals-Chirurgie. 76. Jahresversammlung der Deutschen Gesellschaft für Hals-Nasen-Ohren-Heilkunde, Kopf- und Hals-Chirurgie e.V.. Erfurt, 04.-08.05.2005. Düsseldorf, Köln: German Medical Science; 2005. Doc05hno663

The electronic version of this article is the complete one and can be found online at:

Published: September 22, 2005

© 2005 Hambek et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.



Background: Treatment of squamous cell carcinomas of the head and neck consists of surgery, radiation and/or chemotherapy. However, despite complete remission of the disease, many patients suffer from recurrences during a follow up period of 2 years.

Methods: Il-6, Serotonin, G-CSF and EGF were used to stimulate G0-phase head and neck cancer cells before treatment with Cisplatin. The proportion of G0-phase cells has been detected by multi color FACS analysis and Ki67 staining.

Results: The combination of highest efficacy to provoke cell cycle reentry has been Serotonin + EGF. This combination has then been used to stimulate cancer cells for chemotherapy with cisplatin. The total amount of G0 phase cells has been significantly reduced after 2-fold Serotonin/EGF coincubation. The prestimulation group showed a significant reduced amount of G0-cells. Furthermore, the total amount of A431, Detroit 562 and UM-SCC 10B cells has been significantly reduced in the prestimulation group compared to the control and cisplatin (without prestimulation) group.

Conclusions: Our investigation demonstrates for the first time that G0 cells of head and neck carcinomas are available for treatment after targeted stimulation with growth factors. This provides a new insight in tumor physiology and should lead to reconsideration of established treatment regimen.